SAGIMET BIOSCIENCES INC

Sagimet Biosciences is a clinical-stage biopharmaceutical company whose core business model involves the development of novel therapeutics for metabolic diseases and cancer. The company’s primary drug candidates are small molecules designed to inhibit fatty acid synthase (FASN), a key enzyme in lipid synthesis. The pre-clinical and clinical development of these pharmaceutical products inherently requires animal testing to satisfy regulatory safety and efficacy standards. This reliance on animal models for research and development constitutes commercial exploitation of animals under the firm’s animal exploitation exclusion policy.

The company’s lead product candidate, denifanstat, has progressed through multiple clinical trial phases for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). The pathway to such clinical trials necessitates extensive animal studies. While specific details of Sagimet’s animal testing protocols are not publicly disclosed in the provided evidence, the nature of its business and its position in the pharmaceutical development pipeline confirms a material and ongoing dependence on animal-based research.